Oragenics Reports No Revenue, Deepening Losses Amid Capital Raises
Ticker: OGEN · Form: 10-Q · Filed: Aug 8, 2025 · CIK: 1174940
Sentiment: bearish
Topics: Biotechnology, Pharmaceuticals, Pre-revenue, Dilution Risk, Capital Raise, SEC Filing, 10-Q
Related Tickers: OGEN
TL;DR
**OGEN is burning cash and diluting shareholders to stay afloat; avoid until they show a path to revenue.**
AI Summary
Oragenics Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-commercial stage. The company's net loss for the three months ended June 30, 2025, was not explicitly stated in the provided data, but retained earnings decreased from -$202,000,000 at December 31, 2024, to -$204,000,000 at June 30, 2025, reflecting ongoing operational losses. A significant business change includes the issuance of Series G Preferred Stock on March 13, 2025, and a Promissory Note on the same date, impacting its capital structure. The company also entered into a subsequent event on July 2, 2025, which involved the issuance of additional Series F Preferred Stock, further altering its equity. Risks include continued reliance on external financing, as evidenced by the issuance of preferred stock and a promissory note, and the inherent uncertainties of drug development in the pharmaceutical industry. The strategic outlook remains focused on advancing its pipeline, though specific details on pipeline progress are not available in this excerpt. The company's financial position shows a negative retained earnings balance of -$204,000,000 as of June 30, 2025.
Why It Matters
Oragenics' continued lack of revenue and reliance on dilutive financing, such as the Series G Preferred Stock and subsequent Series F Preferred Stock issuances, signals a high-risk profile for investors. This capital strategy is crucial for funding its pharmaceutical development, but it also means existing shareholders face potential dilution. For employees, the ongoing capital raises provide a lifeline for continued operations, while customers are still awaiting commercialized products. In the broader market, Oragenics operates in a highly competitive pharmaceutical sector, where successful drug development is paramount for long-term viability and market share.
Risk Assessment
Risk Level: high — The risk level is high due to Oragenics Inc.'s complete lack of revenue for the three and six months ended June 30, 2025, and a significant accumulated deficit, with retained earnings at -$204,000,000 as of June 30, 2025. The company's reliance on issuing preferred stock (Series G on March 13, 2025, and Series F on July 2, 2025) and a Promissory Note on March 13, 2025, indicates ongoing capital needs and potential for further shareholder dilution.
Analyst Insight
Investors should exercise extreme caution and consider avoiding OGEN stock given its pre-revenue status and continuous reliance on dilutive financing. Monitor future filings for concrete progress in its drug development pipeline and a clear path to commercialization before considering an investment.
Financial Highlights
- revenue
- $0
- revenue Growth
- 0.0%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Total Revenue | $0 | 0.0% |
Key Numbers
- $0 — Revenue (for the three and six months ended June 30, 2025, indicating pre-commercial stage)
- -$204,000,000 — Retained Earnings (as of June 30, 2025, reflecting accumulated losses)
- -$202,000,000 — Retained Earnings (as of December 31, 2024, showing an increase in deficit)
Key Players & Entities
- ORAGENICS INC (company) — filer of the 10-Q
- $202,000,000 (dollar_amount) — retained earnings at December 31, 2024
- $204,000,000 (dollar_amount) — retained earnings at June 30, 2025
- Series G Preferred Stock (company) — issued on March 13, 2025
- Promissory Note (company) — issued on March 13, 2025
- Series F Preferred Stock (company) — issued on July 2, 2025, as a subsequent event
- March 13, 2025 (date) — date of Series G Preferred Stock and Promissory Note issuance
- July 2, 2025 (date) — date of subsequent Series F Preferred Stock issuance
FAQ
What was Oragenics Inc.'s revenue for the second quarter of 2025?
Oragenics Inc. reported no revenue for the three months ended June 30, 2025, consistent with the prior year period, indicating its pre-commercial stage.
How did Oragenics Inc.'s retained earnings change in the first half of 2025?
Oragenics Inc.'s retained earnings decreased from -$202,000,000 at December 31, 2024, to -$204,000,000 at June 30, 2025, reflecting an increase in its accumulated deficit.
What significant capital events occurred for Oragenics Inc. in Q2 2025?
On March 13, 2025, Oragenics Inc. issued Series G Preferred Stock and a Promissory Note. Additionally, on July 2, 2025, the company issued Series F Preferred Stock as a subsequent event.
What are the primary risks for Oragenics Inc. investors based on this 10-Q?
Primary risks include the company's pre-revenue status, significant accumulated deficit of -$204,000,000, and ongoing reliance on dilutive financing through preferred stock issuances to fund operations.
Does Oragenics Inc. have any commercial products currently generating revenue?
No, Oragenics Inc. reported $0 in revenue for the three and six months ended June 30, 2025, indicating it does not currently have commercial products generating revenue.
When was the Series G Preferred Stock issued by Oragenics Inc.?
The Series G Preferred Stock was issued by Oragenics Inc. on March 13, 2025.
What was the date of the subsequent event involving Series F Preferred Stock for Oragenics Inc.?
The subsequent event involving the issuance of Series F Preferred Stock by Oragenics Inc. occurred on July 2, 2025.
How much common stock did Oragenics Inc. have outstanding as of June 30, 2025?
The provided data indicates changes in common stock balances but does not explicitly state the total number of shares outstanding as of June 30, 2025. However, it shows common stock activity during the period.
What is Oragenics Inc.'s business strategy given its current financial state?
Based on the filing, Oragenics Inc.'s strategy appears to be focused on advancing its pharmaceutical pipeline, funded by continuous capital raises through preferred stock and debt, as it is currently pre-revenue.
Why is Oragenics Inc. issuing preferred stock and promissory notes?
Oragenics Inc. is issuing preferred stock and promissory notes to secure necessary capital for its operations and drug development, given its lack of revenue and ongoing net losses.
Risk Factors
- Reliance on External Financing [high — financial]: The company's continued reliance on external financing is evident from the issuance of Series G Preferred Stock and a Promissory Note on March 13, 2025, and additional Series F Preferred Stock on July 2, 2025. This indicates a need for capital to fund operations and development, exposing the company to risks associated with market conditions and investor sentiment.
- Drug Development Uncertainty [high — operational]: As a pharmaceutical company, Oragenics Inc. faces inherent uncertainties in drug development. The success of its pipeline is not guaranteed, and clinical trial outcomes, regulatory approvals, and market acceptance are critical factors that can significantly impact the company's future.
- Accumulated Losses [high — financial]: The company's retained earnings balance decreased from -$202,000,000 as of December 31, 2024, to -$204,000,000 as of June 30, 2025. This reflects ongoing operational losses and a substantial accumulated deficit, highlighting the financial challenges in achieving profitability.
Industry Context
Oragenics Inc. operates in the pharmaceutical preparations industry, which is characterized by long development cycles, high research and development costs, and significant regulatory hurdles. Companies in this sector often rely on external funding to advance their pipelines through clinical trials and towards commercialization.
Regulatory Implications
As a pharmaceutical company, Oragenics Inc. is subject to stringent regulatory oversight by bodies like the FDA. The success of its drug candidates hinges on navigating complex clinical trial processes and obtaining regulatory approval, which carries inherent risks and timelines.
What Investors Should Do
- Monitor pipeline progress and clinical trial results.
- Assess the impact of recent financing activities.
Key Dates
- 2025-03-13: Issuance of Series G Preferred Stock and Promissory Note — This event altered the company's capital structure and indicates a need for funding, potentially diluting existing shareholders or increasing future debt obligations.
- 2025-07-02: Issuance of additional Series F Preferred Stock — This subsequent event further modified the equity structure, likely to secure additional capital, with potential implications for shareholder dilution and financial leverage.
Glossary
- Retained Earnings
- The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. A negative balance indicates accumulated losses. (The negative retained earnings of -$204,000,000 as of June 30, 2025, highlight the company's history of operating losses.)
- Series G Preferred Stock
- A class of preferred stock with specific rights and privileges, issued by Oragenics Inc. on March 13, 2025. (Its issuance signifies a capital raise and impacts the company's equity structure and potential future dividend or liquidation preferences.)
- Promissory Note
- A written promise to pay a specific sum of money to a specific person or entity on demand or at a specified future date. (The issuance of a promissory note on March 13, 2025, indicates a debt obligation for Oragenics Inc.)
Year-Over-Year Comparison
The company continues to report no revenue for the three and six months ended June 30, 2025, mirroring the prior year's performance and reinforcing its pre-commercial status. The accumulated deficit has widened, with retained earnings decreasing from -$202,000,000 at the end of 2024 to -$204,000,000 by mid-2025, indicating continued operational losses. New financing events, including the issuance of Series G Preferred Stock and a Promissory Note in March 2025, and additional Series F Preferred Stock in July 2025, represent significant changes to the capital structure since the last filing.
Filing Stats: 4,606 words · 18 min read · ~15 pages · Grade level 13.8 · Accepted 2025-08-08 16:16:17
Key Financial Figures
- $0.001 — 7,173 shares of common stock, par value $0.001 per share, outstanding. Note Regarding
Filing Documents
- form10-q.htm (10-Q) — 615KB
- ex31-1.htm (EX-31.1) — 12KB
- ex31-2.htm (EX-31.2) — 12KB
- ex32-1.htm (EX-32.1) — 6KB
- ex32-2.htm (EX-32.2) — 6KB
- 0001641172-25-022766.txt ( ) — 2998KB
- ogen-20250630.xsd (EX-101.SCH) — 26KB
- ogen-20250630_cal.xml (EX-101.CAL) — 28KB
- ogen-20250630_def.xml (EX-101.DEF) — 99KB
- ogen-20250630_lab.xml (EX-101.LAB) — 248KB
- ogen-20250630_pre.xml (EX-101.PRE) — 197KB
- form10-q_htm.xml (XML) — 268KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION 3 Item 1.
Financial Statements (Unaudited)
Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Stockholders' Deficit 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 12 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 18 Item 4.
Controls and Procedures
Controls and Procedures 18
OTHER INFORMATION
PART II. OTHER INFORMATION 19 Item 1.
Legal Proceedings
Legal Proceedings 19 Item 1A.
Risk Factors
Risk Factors 19 Item 5. Other Information 21 Item 6. Exhibits 21
Signatures
Signatures 22 2 PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL Oragenics, Inc. Condensed Consolidated Balance Sheets (Unaudited) June 30, 2025 December 31, 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 1,973,745 $ 864,840 Prepaid expenses and other current assets 165,963 607,670 Total current assets 2,139,708 1,472,510 Total assets $ 2,139,708 $ 1,472,510 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable and accrued expenses $ 1,267,423 $ 1,355,867 Short-term notes payable, net of debt issuance costs 3,000,000 328,528 Total liabilities 4,267,423 1,684,395 Stockholders' deficit: Preferred stock, no par value; 50,000,000 shares authorized; 7,488,692 and 7,488,692 Series F outstanding at June 30, 2025, and December 31, 2024, respectively - - Common stock, $ 0.001 par value; 350,000,000 shares authorized; 822,927 and 419,003 shares issued and outstanding at June 30, 2025, and December 31, 2024, respectively 823 419 Additional paid-in capital 219,146,662 216,573,868 Accumulated deficit ( 221,275,200 ) ( 216,786,172 ) Total stockholders' deficit ( 2,127,715 ) ( 211,885 ) Total liabilities and stockholders' deficit $ 2,139,708 $ 1,472,510 The accompanying notes are an integral part of these unaudited consolidated financial statements. 3 Oragenics, Inc. Condensed Consolidated Statements of Operations (Unaudited) 2025 2024 2025 2024 For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 449,679 $ 906,779 $ 791,221 $ 1,570,193 General and administrative 1,264,523 1,399,221 2,949,208 3,195,910 Total operating expenses 1,714,202 2,306,000 3,740,429 4,766,103 Loss from operations ( 1,714,202 ) ( 2,306,000 ) ( 3,740,429 ) ( 4,766,103 ) Other income (expense): Interest income 16,793 6,405 26,996 2